Thursday, July 2, 2015
Eolas Therapeutics, a therapeutic development company based in Carlsbad, Calif., has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the NIH for the development of the program from the preclinical stage through phase I clinical trials.
Syndax Pharmaceuticals, a privately held oncology company based in Waltham, Mass., has announced that Briggs W. Morrison, M.D., is joining the company as CEO and a member of the board of directors, and Michael A. Metzger is joining the company as president and chief operating officer. Morrison joins Syndax from AstraZeneca, where he was executive vice president, global medicines development and chief medical officer. Metzger joins from Regado Biosciences, where he was president and CEO through the company’s strategic merger with Tobira Therapeutics.
AstraZeneca has partnered with two Algerian companies, AHT Health SARL of SALHI group and Hasnaoui Finance SARL Group. The companies have created the joint venture AstraZeneca Al Djazair to build a new production unit in Algeria. This commitment, which will generate investments and skilled jobs, is part of the Algerian government’a strategy to modernize and develop the pharmaceutical sector of the country. The new facility would formulate AstraZeneca medicines in cardiovascular diseases, gastroenterology, oncology and diabetes for the Algerian healthcare community.
AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. The new facility will supply medicines for clinical trial programs of AZ and MedImmune, the company’s global biologics R&D arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.
AstraZeneca has formed collaborations with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes, and with Abbott to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy tralokinumab.
Surface Oncology, a Cambridge, Mass.-based provider of next-generation cancer immunotherapies, has appointed Detlev Biniszkiewicz, Ph.D., president and CEO, effective immediately. Biniszkiewicz brings over 15 years of industry leadership and experience building a transformative pipeline of novel cancer therapies, most recently as the head of the oncology strategy at AstraZeneca.